Emerald Health Therapeutics Archives

StaffJuly 5, 2022

On Monday, Canadian-based Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) reported its financial results for the year ended December 31, 2021, and gave an update on its plans to exit the cannabis industry. Total revenue for Emerald Health in 2021 fell to C$11.8 million from last year’s C$14.2 million.

In 2021, the company stated that it planned to sell off its cannabis properties and focus on pharmaceutical development. The company hired Vantage Point Advisors to see which companies would be interested in a strategic merger to help the transition from the recreational and medical cannabis business.

Emerald said that after reviewing several companies it decided to go with Skye Bioscience Inc (OTC: SKYE). Skye will issue the company’s shareholders 1.95 shares of Skye’s common stock in exchange for each company share. Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs.

Cannabis Exit

Emerald said that its Victoria, BC operation, the lease on one of its facilities expired on February 28, 2022, and the lease for the remaining facility expired on May 31, 2022. The company continues to rent both facilities on a month-to-month basis in order to maintain its Health Canada-issued license under the Cannabis Act to produce and sell cannabis products. The company said it has fully wound down all operations at the Victoria facilities as of June 1, 2022. Emerald is pursuing the sale of its licenses, brands and processing equipment in relation to its Victoria locations.

At its St. Eustache, QC operation, growing, and processing of cannabis continued until June 30, 2022. In the first quarter of 2022, the company said it retained agents to assist in the sale of the cannabis production operation as a continuing operation. The company has not yet entered into a binding sale agreement with respect to this facility and the selling process is ongoing. Throughout the discontinuation process, the company retained its cannabis sales agreements with the various provinces and continued to sell newly produced and inventoried cannabis dried flower and oils at a reduced volume until June 30, 2022.

On April 14, 2022, the company entered into an agreement with the landlord for its Metro Vancouver greenhouse facility under which the lease obligation related to the facility, which extends to 2047, would be terminated effective December 31, 2022, in exchange for transfer to the landlord of the non-leased equipment owned by the company at the site facility. The Company also has an option to terminate early. On April 28, 2022, the company entered into an amending agreement with FlowerPod LLC, amending the December 28, 2021, binding term sheet payment schedule to $0.75 million on closing and a $0.75 million promissory note bearing 10% interest per annum. The company continues to retain the two-year interest-bearing promissory note issued by FlowerPod on May 6, 2021, in the amount of $0.35 million.

Debra BorchardtJune 19, 2020

Earnings were reported by both Emerald Health Therapeutics (OTCQX: EMHTF) and Terra Tech (OTC:TRTC). This is a quick summary of what the companies reported.

Terra Tech

With cash dwindling at Terra Tech and expenses rising, the company announced it would begin selling assets in order to focus on the properties with the highest returns. The company also said it was postponing its plans to enter the CBD market.

Terra Tech Corp. reported revenues of $4.31 million versus $2.05 million for the quarter ending March 31, 2019, an increase of approximately $2.26 million. The net loss for the quarter was $17.33 million, or $0.11 per basic and diluted share versus $11.74 million, or $0.13 per basic and diluted share, for the three months ending March 31, 2019.

The company had $0.95 million in cash as of March 31, 2020. Expenses were approximately $9.04 million, compared to approximately $8.59 million for the same quarter last year, an increase of approximately $0.45 million.

Matthew Morgan, Chief Executive Officer of Terra Tech, commented, “Our first-quarter results demonstrate continued improvement in our cannabis operations, driven by both medical and adult-use sales from our San Leandro Blüm dispensary as well as wholesale revenues. Following the COVID-19 pandemic, which has resulted in many retailers delaying purchase decisions and reversing plans to launch new CBD products in stores, it has become clear to us that we must focus on our THC business in California to maximize near-term revenues. We have therefore chosen to postpone our expansion strategy in the CBD market through our OneQor business.”

Morgan went on to add, “For us to advance our strategy, we are now completing a number of asset sales in order to strengthen the Company’s cash position and redirect resources to assets that generate the highest returns. We expect to have approximately $24 million coming in from asset sales over the next 12 months from our Blüm dispensaries in Nevada and Santa Ana, California, as well as various sales of non-core licenses and properties. This is expected to set the Company on a path to sustainability that will allow us to be lean and cost-effective. We intend to complete the build out of our Hegenberger cultivation facility in California and leverage our existing capital base to ramp revenues from wholesale THC products as well as sales at our Blüm dispensaries in San Leandro and Oakland.”

Emerald Health

Emerald Health net sales increased 36% to $2.9 million over last year’s $2.1 million for the same time period. The net loss for the quarter was still elevated at $4.9 million, which included a $2 million loss on the dilution of joint venture ownership and a $1.1 million inventory write-down.

The company reported that its total SG&A expenses of $6.0 million showed a decrease of $2.3 million over $8.3 million expense in the comparable first quarter of 2019. Total SG&A expense included $2.1 million of non-cash or non-recurring items.

“In the first quarter and year to date, the benefits of Emerald’s significant restructuring and cost-rationalization are strongly emerging. While these benefits were not fully realized in our Q1 financials, we can see our operational metrics and financial results clearly moving in the desired direction,” said Riaz Bandali, President and Chief Executive Officer of Emerald. “In not even two full quarters, our two newly launched and scaled-up cultivation facilities in BC and Quebec have been achieving important milestones and are positioned to move us toward profitably. On top of that we own over 41% of one of the premiere large-scale cannabis cultivation operations in the country.”

The company said that revenue for the quarter was driven by increased sales from the adult-use market where sales were up 35% as compared to 4Q19. 30% of revenue in the adult-use channel from SYNC oils contributed to improving margins, as this high CBD, low THC oil is not subject to excise duty. A higher proportion of sales from the branded SYNC oil, coupled with the lower cost of dried flower contributed to improved margins compared to 1Q19. Significant harvests from the newly operational production sites led to capitalized inventory, which reflected as a further improvement in production costs. Emerald recognized $5.2 million as its share of net income from Pure Sunfarms, as compared to $5.8 million recognized 1Q19.

StaffMay 14, 2020

Emerald-Health-Takes-Cannabis-Industry-by-Storm-400x225.jpg

Emerald Health Therapeutics, Inc. (OTCQX: EMHTF) reported financial results for the quarter and year ending December 31, 2019. Net sales were $20.3 million in 2019 versus $1.9M in 2018. The company reported a staggering net loss of $111.9 million in 2019, which it said was impacted by a non-cash impairment charge of $65 million related to the Verdélite production facility in Quebec. The stock fell over 6% on the news.

In addition to that charge, $14 million non-cash loss related to the settlement of outstanding issues related to the Pure Sunfarms joint venture, and a $6 million inventory write-down.

Fourth Quarter

Net sales for the fourth quarter were $4.3 million, an increase of 340% from the same period in 2018. The net loss for the quarter was $90 million

“In the second half of 2019 and through the beginning of 2020, our focus has been to cut costs, scale-up commercial production in our two wholly-owned cultivation facilities, and continue our progress toward positive cash flow and profitability,” said Riaz Bandali, President and Chief Executive Officer of Emerald. “We have four distinct assets encompassing cultivation, post-harvest processing, and product development based on science and unique intellectual property.”

Pure Sunfarms

The company has restructured its commitments and relationship with its joint venture, Pure Sunfarms, and its joint venture partner, Village Farms, resulting in the termination of all supply agreements and related obligations. Emerald retains 41.3% ownership and 3 of 6 board seats in Pure Sunfarms. Emerald recognized $19.6 million in a net gain as its share of the joint venture’s net earnings for 2019.

The net sales for Pure Sunfarms consisted entirely of dried cannabis, for the year and fourth quarter of 2019 were $82.8M and $12.1M, respectively, compared to $4.9M and $4.7M in 2018. The gross revenue for Pure Sunfarms fell by 45% sequentially to $13.5 million in the fourth quarter from $24.8 million in the third quarter.

Other Business

In the fourth quarter, Emerald fulfilled its first shipment of premium cannabis products to the Nova Scotia Liquor Corporation for the adult-use market. This first shipment consisted of Emerald’s high potency SYNC 25 CBD oil and dry cannabis flower, bringing distribution to 10 provinces and territories.

Medical sales continued to grow quarter over quarter, with our patient base almost doubling to 5000 since the beginning of the year. Sales grew 85% from the previous year.

Kaitlin DomangueJanuary 28, 2020

Emerald Health Therapeutics (TSXV: EMH; OTCQX: EMHTF), referred to as “Emerald” for clarity, is a Canadian cannabis company offering wellness-oriented and recreational cannabis products. Emerald provided an update yesterday on their recently announced a shares for debt transaction with Emerald Health Sciences, (“Sciences”) a control person for Emerald.

Presently, Emerald carries an aggregate debt of $2,816,963. Per a previously disclosed loan agreement between both parties, Emerald will settle $794,182 owed to Sciences, as well as $2,022,781 owed to Sciences pursuant to trades payable. Emerald Health Therapeutics will also issue 9,713,666 common shares of Emerald to Sciences at $0.29 per share in order to fulfill the debt.

Currently, Sciences holds roughly 29,687,942 of Emerald’s issued shares and upon the completion of the debt settlement, Sciences will hold approximately 23.1% of the issued and outstanding shares of Emerald, on an undiluted basis.

Due to Sciences being a control person of Emerald, the settlement is considered to be a “related party transaction”, meaning the companies had a pre-existing connection prior to the transaction.

Emerald is not the only company in a cash crunch, and relying on selling common shares to stay above water. MedMen has also been making the headlines for a similar situation. The company recently sent out emails to their vendors stating they cannot pay them, and are offering shares in their company instead.

Green Market Report talked to Adam Bierman, the CEO of MedMen, about their circumstances. Bierman tells us, “We’ve been very forthright with the public, and with our investment community at large about the fact that at the end of last year we entered into a restructuring in the business, exiting the hyper-growth stage of the business, and getting into sustainability, and with that, there’s a lot of pain. And that pain starts at the employees that were on this mission with us, building this platform with us that we had to part ways with.”

William SumnerOctober 7, 2019

It’s time for your Daily Hit of cannabis financial news for October 7, 2019.

On the Site

NBA Veteran Al Harrington’s Viola Closes on $16m Financing Round

NBA veteran Al Harrington’s Viola closed on a $16 million funding round led by Gotham Green Partners. This is the first institutional investment in the company. The company said that this latest round of funding will assist with the acquisition of a 34,500 sq. ft cultivation, processing and distribution facility in Adelanto, California as well as the completion of Viola’s 48,000 sq. ft facility in Detroit, Michigan. The funds will also enable Viola to continue to advance the growth of the company’s personnel with key new hires that will continue to establish Viola as a leader in the cannabis marketplace.

Surterra Wellness

Surterra Wellness today announced that it has changed its corporate name to Parallel effective today. In June, Private cannabis company Surterra Wellness closed on the initial $100 million Series D funding round and expanded its Board of Directors. The company noted back then that the participants in the round included existing and new investors including former Patrón Spirits Company CEO, Ed Brown.

The Power That Data Has On Brand

Knowledge is power and the more data you have the better choices you can make for your brands. Akerna has been gathering data through its MJ Platform and will demonstrate how this data can be used for success with your brand. This panel was taped at the green Market Summit on September 11 in Los Angeles.

In Other News

TerrAscend

TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) announced that Health Canada has approved the company’s plan to expand its facility in Mississauga, Ontario from from 17,800 sq. ft. to 51,800 sq. ft. The expansion will include additional cultivation capacity, a commercial kitchen, formulation rooms and increased primary and secondary packaging capacity. “Achieving this approval milestone is a crucial step in our plan to cultivate premium grade cannabis at scale for distribution to the EU and other international markets,” said Michael Nashat, CEO of TerrAscend.

Emerald Health Therapeutics

Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF) announced that its subsidiary, Verdélite, has a received a license amendment from Health Canada for the complete growing and processing area in its 88,000 square foot indoor facility. This will allow the company to increase its production space from 4 to 21 highly-controlled-environment grow rooms and to a total of 16 processing rooms. “This new license amendment allows Verdélite to transition into its full commercial phase and positions Verdélite as a key growth contributor to Emerald’s financial results in 2020,” said Riaz Bandali, CEO of Emerald Health.

William SumnerJune 13, 2019

Although adult-use cannabis is legal in nine U.S. states, problems persist with companies trying to gain access to capital and essential financial services. Consequently, the industry has devised a series of methods and institutions to circumvent these difficulties; from credit unions to keeping their funds in a giant safe. Another unique way that the cannabis industry has adapted to the issue has been connecting companies with private capital investment through investor forums. A perfect example of this is the MJMicro Conference planned for June 25, 2019, in New York City.

MJMicro is an invitational investor forum aimed at connecting high net worth investors with C-level executives of cannabis companies that have proof of concept, revenue streams, audited financials, and valuations justified by public markets.

The conference is hosted by MjLink.com Inc., a wholly-owned subsidiary of Social Life Networks, Inc. (OTC: WDLF). George Jage is President of MjLink.com, which is an A.I. and Blockchain powered cannabis social network technology company that launched one of the first cannabis social network platforms in the United States and Canada, back in early 2013.

In addition to a fireside chat with two of the leading cannabis companies in the industry, Canopy Growth (NYSE: CGC) and Acreage Holdings (OTCMKTS: ACRGF), several companies have been selected to host spotlight presentations during the conference. Those companies include Emerald Health Therapeutics (CVE: EMH), FSD Pharma (OTCMKTS: FSDDF), and Helix TCS (OTCMKTS: HLIX).

Emerald Health Therapeutics is a medical cannabis company licensed to operate in Canada. The company’s subsidiary, Emerald, both produces and sells medical cannabis and has a stake in a company that produces, cultivates and distributes wholesale cannabis and cannabis extracts for both adult-use and medicinal purposes.

Most recently, Emerald Health was appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its International Affairs Council on CBD and Hemp in ATACH’s engagement with the US Food & Drug Administration’s public hearing on CBD regulations.

Acting as a subsidiary of FV Pharma Inc., FSD Pharma focuses on developing high quality indoor-grown medical cannabis and the development of novel cannabinoid-based treatments for several central nervous system disorders. The company is currently engaged in expanding its 25,000 square foot cultivation facility in Ontario.

Helix TCS provides infrastructure services for the cannabis industry. Though the company may not be a household name, several of its subsidiaries are more recognizable; including Helix Security, Cannabase, and the seed-to-sale tracking software company BioTrackTHC. Tracking over $18 billion in legal cannabis sales, Helix TCS’s products are used in six countries, 36 U.S. states, and over 2,000 licensed retail locations.

In addition to the spotlight presentations by Emerald Health, FSD Pharma, and Helix TCS; several notable cannabis companies are also set to present at MJMicro. Those companies include MJ Freeway, Dixie Brands., Vireo Health, and more.

Jage was the lead executive and driving force behind the development of Marijuana Business Daily and the success of MJBizCon from 2014 through 2017 and most recently he took the helm at Dope Media and successfully negotiated the acquisition by the High Times Holding Corp. His events have been recognized by Tradeshow Week (2006, 2008, 2009) and Tradeshow Executive (2016, 2017) as one of the fastest growing events in the U.S. He has been awarded UNLV’s Jerry Valen Award of Distinction (2010) and the Nevada Entrepreneur Award (2008), and named as the Trade Show Elite (2013) and Gourmet News’s Top 20 Under 40 (2006).

Green Market Report is a media partner of this event.

Organigram Holdings Seeks C$500 Million Financing Approval

Lucy Scientific Mum on High Times Deal

In other news

2023 Notable Leaders in Cannabis: Luna Stower

Number of the Week: $50.7 Billion

Green Market Report New York Awards: Best Lawyer Benjamin Rattner

Emerald Health Therapeutics Archives - Green Market Report

Emerald Health Gives Update on Cannabis Exit

Cannabis Exit

Earnings Roundup: Terra Tech, Emerald Health

Emerald Health Stock Falls On Earnings

Emerald Using Shares to Pay Bills